» Articles » PMID: 32509575

CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1α Pathway

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Jun 9
PMID 32509575
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) is a major serious malignant tumor and is commonly diagnosed in older men. Identification of novel cancer-related genes in PCa is important for understanding its tumorigenesis mechanism and developing new therapies against PCa. Here, we used RNA sequencing to identify the specific genes, which are upregulated in PCa cell lines and tissues. The cell division cycle associated protein (CDCA) family, which plays a critical role in cell division and proliferation, is upregulated in the PCa cell lines of our RNA-Sequencing data. Moreover, we found that is overexpressed, and its protein level positively correlates with its histological grade, clinical stage, and Gleason Score. CDCA2 was further found to be upregulated and correlated with poor prognosis and patient survival in multiple cancer types in The Cancer Genome Atlas (TCGA) dataset. The functional study suggests that inhibition of CDCA2 will lead to apoptosis and lower proliferation . Silencing of CDCA2 also repressed tumor growth . Loss of CDCA2 affects several oncogenic pathways, including MAPK signaling. In addition, we further demonstrated that was induced in hypoxia and directly regulated by the HIF-1α/Smad3 complex. Thus, our data indicate that CDCA2 could act as an oncogene and is regulated by hypoxia and the HIF-1αpathway. may be a useful prognostic biomarker and potential therapeutic target for PCa.

Citing Articles

CDCA genes as prognostic and therapeutic targets in Colon adenocarcinoma.

Zhao Z, Feng X, Chen B, Wu Y, Wang X, Tang Z Hereditas. 2025; 162(1):19.

PMID: 39924497 PMC: 11809055. DOI: 10.1186/s41065-025-00368-w.


A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma.

Li W, Lv D, Yao J, Chen B, Liu H, Li W PLoS One. 2023; 18(9):e0291024.

PMID: 37733705 PMC: 10513342. DOI: 10.1371/journal.pone.0291024.


Prognostic value of cell division cycle-associated protein-3 in prostate cancer.

Gu P, Zhang M, Chen X, Du J, Chen L, He X Medicine (Baltimore). 2023; 102(36):e34655.

PMID: 37682152 PMC: 10489371. DOI: 10.1097/MD.0000000000034655.


Modifications of The Human Liver Cancer Cells through microRNA-145-Mediated Targeting of CDCA3.

Lai Y, Liu J, Hu X, Zeng X, Gao P Cell J. 2023; 25(8):546-553.

PMID: 37641416 PMC: 10542210. DOI: 10.22074/cellj.2023.1995666.1251.


PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.

Xiao F, Jie X, Zhou X, Guo Y, Sun G, Lin L Biosci Rep. 2023; 43(5).

PMID: 37083601 PMC: 10170297. DOI: 10.1042/BSR20230028.


References
1.
Nickols N, Jacobs C, Farkas M, Dervan P . Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol. 2007; 2(8):561-71. PMC: 3060759. DOI: 10.1021/cb700110z. View

2.
Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K . Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest. BMC Cancer. 2012; 12:321. PMC: 3418557. DOI: 10.1186/1471-2407-12-321. View

3.
Zhang Z, Shen M, Zhou G . Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1. Biochem Biophys Res Commun. 2018; 496(2):482-489. DOI: 10.1016/j.bbrc.2018.01.046. View

4.
Shen Z, Yu X, Zheng Y, Lai X, Li J, Hong Y . CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker. Onco Targets Ther. 2018; 11:891-901. PMC: 5824752. DOI: 10.2147/OTT.S154754. View

5.
Zhang Y, Yuan Y, Liang P, Zhang Z, Guo X, Xia L . Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer. Oncotarget. 2017; 8(28):45459-45469. PMC: 5542200. DOI: 10.18632/oncotarget.17564. View